Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 160 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015', provides an overview of the Dry (Atrophic) Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dry (Atrophic) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Dry (Atrophic) Macular Degeneration Overview 10
Therapeutics Development 11
Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 11
Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 12
Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 13
Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 15
Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Dry (Atrophic) Macular Degeneration - Products under Development by Companies 20
Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 22
Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 23
Aciont Inc. 23
Acucela Inc. 24
Alexion Pharmaceuticals, Inc. 25
Alimera Sciences, Inc. 26
Apellis Pharmaceuticals, Inc. 27
Benitec Biopharma Limited 28
Catalyst Biosciences, Inc. 29
Cell Cure Neurosciences, Ltd. 30
Foamix Pharmaceuticals Ltd. 31
Genentech, Inc. 32
GenSight Biologics SA 33
GlaxoSmithKline Plc 34
Icon Bioscience, Inc. 35
MacuCLEAR, Inc. 36
Novartis AG 37
Ocata Therapeutics, Inc. 38
Ophthotech Corp. 39
pSivida Corp. 40
R-Tech Ueno, Ltd. 41
StemCells, Inc. 42
Sun Pharma Advanced Research Company Ltd. 43
U.S. Stem Cell, Inc. 44
Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
AdipoCell - Drug Profile 54
Mechanism of Action 54
R&D Progress 54
APL-2 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
avacincaptad pegol sodium - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BIO-201 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BIO-203 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CLG-561 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Drug for Age Related Macular Degeneration - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
eculizumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
emixustat hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
fluocinolone acetonide SR - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
FMX-103 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Gene Therapy for Ocular Diseases - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GS-030 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GSK-933776 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
HMR-59 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
HuCNS-SC - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ICR-14967 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
lampalizumab - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
MA09-hRPE - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
MC-1101 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
methotrexate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
OCU-100 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ONL-1204 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
OpRegen - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
OpRegen Plus - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
RC-1 Alpha - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
RST-001 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule to Inhibit Amyloid Beta for Glaucoma and Dry AMD - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
tesidolumab - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
TT-231 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
unoprostone isopropyl - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
VM-100 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Dry (Atrophic) Macular Degeneration - Recent Pipeline Updates 106
Dry (Atrophic) Macular Degeneration - Dormant Projects 149
Dry (Atrophic) Macular Degeneration - Discontinued Products 151
Dry (Atrophic) Macular Degeneration - Product Development Milestones 152
Featured News & Press Releases 152
Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN 152
Jul 20, 2015: StemCells Transplants First Patient in Phase II Clinical Trial for Dry Age-Related Macular Degeneration 152
Dec 17, 2013: Bioheart Announces Clinical Study for Dry Macular Degeneration 153
Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 153
Oct 01, 2013: Roche to present data on Lampalizumab at investor event 154
Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 155
Apr 18, 2013: StemCells Adds Byers Eye Institute At Stanford As Second Site For Phase I/II Clinical Trial In Dry Age-related Macular Degeneration 156
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 157
Oct 04, 2012: StemCells Announces First Transplant Of Neural Stem Cells Into Patient In Phase I/II Study For Dry Age-related Macular Degeneration 157
Jun 21, 2012: StemCells Initiates Phase I/II Clinical Trial In Dry Age-Related Macular Degeneration 158
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

List of Tables

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2015 11
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Dry (Atrophic) Macular Degeneration - Pipeline by Aciont Inc., H2 2015 23
Dry (Atrophic) Macular Degeneration - Pipeline by Acucela Inc., H2 2015 24
Dry (Atrophic) Macular Degeneration - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015 25
Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H2 2015 26
Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2015 27
Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2015 28
Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H2 2015 29
Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H2 2015 30
Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 31
Dry (Atrophic) Macular Degeneration - Pipeline by Genentech, Inc., H2 2015 32
Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2015 33
Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2015 34
Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2015 35
Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR, Inc., H2 2015 36
Dry (Atrophic) Macular Degeneration - Pipeline by Novartis AG, H2 2015 37
Dry (Atrophic) Macular Degeneration - Pipeline by Ocata Therapeutics, Inc., H2 2015 38
Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2015 39
Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H2 2015 40
Dry (Atrophic) Macular Degeneration - Pipeline by R-Tech Ueno, Ltd., H2 2015 41
Dry (Atrophic) Macular Degeneration - Pipeline by StemCells, Inc., H2 2015 42
Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 43
Dry (Atrophic) Macular Degeneration - Pipeline by U.S. Stem Cell, Inc., H2 2015 44
Assessment by Monotherapy Products, H2 2015 45
Number of Products by Stage and Target, H2 2015 47
Number of Products by Stage and Mechanism of Action, H2 2015 49
Number of Products by Stage and Route of Administration, H2 2015 51
Number of Products by Stage and Molecule Type, H2 2015 53
Dry (Atrophic) Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2015 106
Dry (Atrophic) Macular Degeneration - Dormant Projects, H2 2015 149
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H2 2015 150
Dry (Atrophic) Macular Degeneration - Discontinued Products, H2 2015 151